Enhanced resistance to chemotherapy has been correlated with high levels of Delta-Np73 (DNp73), an anti-apoptotic protein of the p53 tumor-suppressor family which inhibits the pro-apoptotic members such as p53 and TAp73. Although genotoxic drugs have been shown to induce DNp73 degradation, lack of mechanistic understanding of this process precludes strategies to enhance the targeting of DNp73 and improve treatment outcomes. Antizyme (Az) is a mediator of ubiquitin-independent protein degradation regulated by the polyamine biosynthesis pathway. We show here that acetylpolyamine oxidase (PAOX), a catabolic enzyme of this pathway, upregulates DNp73 levels by suppressing its degradation via the Az pathway. Conversely, downregulation of PAOX activity by siRNA-mediated knockdown or chemical inhibition leads to DNp73 degradation in an Az-dependent manner. PAOX expression is suppressed by several genotoxic drugs, via selected members of the activator protein-1 (AP-1) transcription factors, namely c-Jun, JunB and FosB, which are required for stress-mediated DNp73 degradation. Finally, chemical-and siRNA-mediated inhibition of PAOX significantly reversed the resistant phenotype of DNp73-overexpressing cancer cells to genotoxic drugs. Together, these data define a critical mechanism for the regulation of DNp73 abundance, and reveal that inhibition of PAOX could widen the therapeutic index of cytotoxic drugs and overcome DNp73-mediated chemoresistance in tumors.
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Similar to p53, transactivation competent TAp73 exerts tumor-suppressive activities via the regulation of apoptotic signaling and cell-cycle arrest. 2 However, the DNp73 form, which lacks the N-terminal transactivation domain, works as a dominant-negative inhibitor of both TAp73 and p53 and therefore inhibits their tumor-suppressor functions. 3 It is noteworthy that DNp73 also possesses weak transcriptional activity and is able to transactivate several genes such as 14-3-3 and Gadd45, 4 and was recently shown to induce the expression of anti-apoptotic proteins caspase-2S and hsp70, 5, 6 further illustrating its anti-apoptotic potential.
Consistently, DNp73
À / À mouse embryonic fibroblasts were found to be sensitized to genotoxic stresses and showed enhanced p53-dependent apoptosis, indicating that DNp73 is a critical inhibitor of apoptosis. 7 Not surprisingly, DNp73 expression is frequently elevated in many human cancers, including lung, neuroblastoma, colon, ovarian, liver, etc., [8] [9] [10] which suggests a role in either promoting cellular growth or inhibiting apoptosis, as well as in affecting chemosensitivity. In the latter context, TAp73 and p53 are activated by a multitude of chemotherapeutic agents, 11 linking their functions to the chemosensitivity of cancer cells. Thus, DNp73 overexpression would be one mechanism of inhibiting TAp73-and p53-dependent pro-apoptotic activity in response to chemotherapeutic drugs, leading to poor clinical outcome. 12, 13 Consistently, exposure to genotoxic signals leads to the upregulation of TAp73 and the downregulation of DNp73, 14 hence allowing an effective apoptotic response to ensue. This indicates that the relative abundance of the two forms of p73 could be an important determinant of cellular fate during stress response, thereby regulating chemosensitivity.
Owing to their homology, TAp73 and DNp73 protein stability are regulated by many common factors, including Itch, c-Abl, PML, NQO1, Cyclin G and others, via both ubiquitin-dependent and -independent mechanisms. degradation of DNp73 by genotoxic stresses occur through the ubiquitin-independent, polyamine-induced antizyme (Az) pathway that is regulated by c-Jun, a member of the activator protein-1 (AP-1) family of transcription factors. 20 Az1 is a small inhibitory protein that binds to its target proteins and directs them to the proteasome for degradation. 21, 22 Az1 transcript exists with two overlapping open reading frames, and translation of a fully functional Az1 protein requires a unique þ 1 ribosomal frameshift mechanism, which is dependent on the level of polyamines, a group of cationic compounds such as putrescine, spermidine and spermine present in the cells 21, 22 ( Figure 1a , lower panel). The balance of polyamines in cells is controlled by several key enzymes, which either synthesize or breakdown the different polyamine by-products. Ornithine is converted into diamine putrescine by the rate-limiting enzyme ornithine decarboxylase (ODC). 22 A second rate-limiting enzyme S-adenosylmethionine decarboxylase (SAMDC) is required for the synthesis of both triamine spermidine and tetramine spermine by spermidine synthase (SPDS) and spermine Figure 1D for raw data) is presented (f). The levels of the intermediate product in the conversion of spermine back to spermidine, NASp was also measured and depicted (g). All values are means ± S.D. of triplicate experiments for g Overcoming DNp73-mediated chemoresistance by suppressing PAOX W Bunjobpol et al synthase (SPMS), respectively 22 ( Figure 1a , upper panel). Conversely, spermine can be converted back to spermidine and the latter to putrescine by catabolic enzymes spermidine/ spermine N 1 -acetyltransferase (SSAT) and acetylpolyamine oxidase (PAOX); 22 involving the intermediates N-acetylspermine (NASp) and N-acetylspermidine. Our previous study has shown that upon genotoxic insults, c-Jun regulates the levels of functional Az to degrade DNp73, but the exact mechanistic details remain unclear.
In addition to c-Jun, the AP-1 transcription factor family also includes JunB, JunD, c-Fos, FosB, Fra1 and Fra2. 23 Through the formation of heterodimers or homodimers, the latter in the case of the Jun proteins, the AP-1 members regulate diverse physiological processes in response to a plethora of stimuli, such as DNA damage, growth factors and oncogenic stimuli. 24 Although AP-1 members can activate a set of common target genes, different AP-1 dimer compositions produce different biological outcomes, suggesting that they can also selectively regulate distinct sets of genes. 25, 26 In addition, some biological effects of AP-1 members are the result of their ability to repress gene expression, such as inhibition of p53 by c-Jun. 27 In this respect, we have investigated the mechanism of DNp73 regulation through the Az pathway with reference to the specificity of AP-1 members in regulating this process. Our results demonstrate that unlike other AP-1 factors, only c-Jun, JunB and FosB are able to specifically repress the expression of polyamine catabolic enzyme paox (the gene encoding PAOX), highlighting the functional specificity of these AP-1 factors. This effect leads to the production of active Az1 that consequently degrades DNp73. In addition, inhibition of PAOX in DNp73-overexpressing cancer cells abrogated their resistance to chemotherapeutic agents and reveals a possible avenue for effective targeted therapy in DNp73-overexpressing cancers in the presence of chemotherapeutic drugs.
Results
Polyamine catabolic enzyme PAOX positively regulates DNp73. We have utilized doxorubicin as a prototypic DNA-damaging chemotherapeutic agent to investigate the effects on the expression of the anabolic and catabolic enzymes that regulate polyamines levels in cells (Figure 1a) . Treatment of p53 null H1299 cells with doxorubicin resulted in the transcriptional downregulation of anabolic enzymes samdc and spds and upregulation of odc and spms (Figure 1b) . Although upregulation of odc and spms would equate to an increase in synthesis of polyamines, silencing of odc or spms did not prevent the stress-mediated degradation of DNp73 (Supplementary Figures 1A and B) . Similarly, although doxorubicin induced ssat expression, siRNAmediated silencing of this enzyme had no major effect on stress-mediated DNp73 degradation (Supplementary Figure 1B) . However, downregulation of paox upon doxorubicin treatment was observed to occur concomitantly with the reduction of DNp73b protein (Supplementary Figure 1C) , and exogenous expression of flag-tagged PAOX alone was able to significantly increase the steady-state levels of DNp73b after doxorubicin treatment (Figure 1c) . Moreover, although doxorubicin treatment led to a reduction of DNp73b, this effect was reduced in the presence of PAOX (Figure 1c) . To further explore the role of PAOX in regulating DNp73 abundance, we silenced paox expression, which resulted in a marked decrease in DNp73b steady-state levels (Figure 1d ). Similar effect was observed on endogenous cyclin D1, another known target of the polyamine-Az degradation pathway (Figure 1d) , with the mRNA of both DNp73 and cyclin D1 remaining unaffected by paox silencing (Figure 1d  lower panel) . Furthermore, treatment of cells that inducibly express DNp73b with a known chemical inhibitor of PAOX, MDL72527, 28 led to a decrease in DNp73 levels in a dose-dependent manner (Figure 1e) .
We further evaluated the effects of the chemotherapeutic agents on the polyamine pathway by determining the levels of polyamines upon doxorubicin or cisplatin treatment (Supplementary Figure 1D) . Although spermine levels were generally unaltered, levels of putrescine were reduced upon treatment (Supplementary Figure 1D) , resulting in an increase in the ratio of spermine to putrescine (Figure 1f) . Importantly, the levels of NASp were significantly reduced after drug treatment (Figure 1g ), consistent with the reduction of paox by treatment with these agents. These data together, demonstrate that the polyamine catabolic enzyme paox that is downregulated upon genotoxic stress is critical in functioning as a regulator of DNp73 levels. We next investigated whether all three AP-1 transcription factors were able to repress paox expression by directly acting on its promoter. For this purpose, we cloned a portion of the paox promoter ( À 3045 to À 997) predicted by TESS (Transcription Element Search System online software) to contain two potential AP-1-binding sites (indicated as P1 and P2 in Figure 2d upper panel) into a luciferase reporter construct. Overexpression of c-Jun and JunB led to a significant decrease, and FosB led to a marginal decrease in paox promoter activity ( Figure 2d , lower left panel) and in parallel, upregulated collagenase promoter activity, a classical target of AP-1 transcription factors 27 ( Figure 2d , lower right panel). Members of the AP-1 transcription factors form heterodimers with each other to regulate many of their target genes 25, 27 and expectedly, AP-1 monomers that were tethered to force specific pairing of c-Jun/FosB and JunB/FosB 26 suppressed paox or activated collagenase to a higher level relative to c-Jun, JunB and FosB alone ( Figure 2d , lower panels). In order to locate the binding sites for AP-1 on the paox promoter, the two predicted repressor sites (P1 and P2) were mutated. As expected, mutations of both P1 and P2 sites increased the basal promoter activity by 410-fold relative to the wild-type paox promoter, indicating that P1 and P2 were indeed the repression sites of these selective AP-1 factors (Figure 2e , left panel). Furthermore, expression of transactivation-deficient mutants of c-Jun (TAM67) or FosB (DFosB), which exert a dominant negative effect on AP-1 transcriptional activity, 29, 30 led to the derepression of the paox promoter, which was not observed upon mutation of the predicted binding sites of AP-1 factors, P1 and P2 ( Figure 2e , right panel). Moreover, the mutant promoter was not suppressed by the AP-1 members (Supplementary Figure 2A) , altogether confirming the requirement of these sites for AP-1-mediated repression of paox.
To determine whether these three AP-1 transcription factors could bind to paox promoter in vivo, we performed chromatin immunoprecipitation (ChIP) of c-Jun, JunB and FosB on regions corresponding to P1 and P2. All three AP-1 members were highly enriched at the predicted sites (Figure 2f ), but significant loading of JunB and FosB only occurred after doxorubicin treatment, whereas c-Jun was generally constitutively bound on P2. Altogether, the data show that selected members of the AP-1 family, namely c-Jun, JunB and FosB, bind to the paox promoter after genotoxic stress to repress its expression. members showed that besides c-Jun, only JunB and FosB were equally competent at decreasing the steady-state levels of DNp73 (Figure 3a ). This effect was further confirmed using the protein synthesis inhibitor cycloheximide (CHX), which revealed that the half-life of DNp73b was significantly extended from 3.5 h to B6 h upon silencing the expression of FosB, JunB (Figure 3b ) or c-Jun (Supplementary Figure 2B) . Conversely, overexpression of these AP-1 members led to a significant reduction in the half-life of DNp73 ( Supplementary Figures 2C and D) . Furthermore, individual silencing of c-Jun, JunB or FosB in DNp73b-inducible H1299 cells before doxorubicin treatment led to the stabilization of DNp73b levels at the basal level, and significantly inhibited the doxorubicin-mediated degradation of DNp73b (Figure 3c ). We further also assessed whether JunB and FosB could degrade DNp73 independently of c-Jun. Overexpression of FosB or JunB, but not Fra1, in mouse embryonic fibroblasts deficient in c-Jun was able to degrade DNp73b to a similar extent as exogenously expressed c-Jun (Figure 3d ), illustrating a clear functional redundancy of these three AP-1 members in regulating DNp73. These data together with the observation that only c-Jun, JunB and FosB can regulate paox expression (Figure 2 ), highlight the specificity of these AP-1 members in degrading DNp73 independently.
AP-1-mediated degradation of DNp73 occurs via the PAOX-Az pathway. As besides c-Jun, JunB and FosB also have the ability to downregulate paox and subsequently degrade DNp73 levels, it is highly likely that Az1(p) processing is a common mechanism regulated by all three AP-1 members. To test this hypothesis, we examined the effects of AP-1 members on Az1(p) production, with addition of putrescine being used as a positive control to induce Az1(p) (Figure 4a, last lane from left) . Overexpression of c-Jun, JunB or FosB, but not Fra1, was able to upregulate Az1(p) expression, with no significant changes in the levels of Az1 mRNA. To validate the role of Az1 in mediating the degradation of DNp73 by JunB and FosB, we used the natural inhibitor of Az1, AZI, to block the function of this pathway. Degradation of DNp73 by JunB or FosB (Figure 4b ), or c-Jun 20 (data not shown) was significantly reduced in the presence of AZI. Similarly, knockdown of Az1 mRNA reduced c-Jun and FosB-mediated DNp73 degradation (Supplementary Figure 3a) . Together, these data confirm the role of Az1 as a downstream effector of all three AP-1 transcription factors to degrade DNp73.
Given that the production of Az1(p) is governed by polyamine biosynthesis, downregulation of catabolic enzyme PAOX by stress signals could lead to elevated polyamine content, thus enhancing Az1(p) production. Inhibition of Figure 3B) . We thus assessed whether suppression of paox is the mechanism employed by these three AP-1 factors to degrade DNp73. To verify this, PAOX was overexpressed to counteract the downregulation of endogenous paox mediated by c-Jun. Co-expression of Flag-tagged PAOX with c-Jun inhibited the reduction of DNp73 levels (Figure 4c ), suggesting that transcriptional repression of paox is indeed mediating the effect of AP-1-dependent degradation of DNp73.
To further confirm the role of PAOX-Az axis in regulating DNp73, we examined whether Az1 was acting downstream of paox. Overexpression of AZI, which inhibits Az1, rescued DNp73 degradation caused by paox knockdown (Figure 4d) . Similarly, silencing of Az1 partially inhibited DNp73 degradation induced by paox silencing (Figure 4e ). Taken together, these data demonstrate that suppression of the polyamine catabolic enzyme paox by c-Jun, JunB and FosB leads to the degradation of DNp73 via the Az pathway.
PAOX inhibition reverses DNp73-dependent chemoresistance. Analysis of human cancer data sets using Oncomine showed that paox was indeed highly expressed in several types of tumors relative to their normal counterparts (Supplementary Figure 4A) , emphasizing a potential clinical relevance of PAOX. Given that DNp73 overexpression leads to resistance to chemotherapeutic drugs such as cisplatin, 5 and that PAOX expression regulates the abundance of DNp73, we assessed whether inhibition of PAOX with MDL72527 can reverse the chemoresistance mediated by DNp73. Treatment with MDL72527 was sufficient for the reduction of DNp73b levels in the SH-SY5Y neuroblastoma cell line overexpressing DNp73b in a dose-dependent manner (Supplementary Figure 4B) . Concomitant cell death analysis revealed that cisplatin treatment resulted in increased cell death only in vector SHSY-5Y cells but not in DNp73b overexpressing cells (% dead cells 0/10/20 mM cisplatin -vector versus Figure 5C ). In addition, siRNA-mediated knockdown of paox before cisplatin treatment also led to sensitization to cell death in DNp73b overexpressing HCT116 (Supplementary Figure 5D) . These data therefore indicate that the protective effect of DNp73 against exposure to chemotherapeutic drugs could be reversed by inhibition of the polyamine catabolic enzyme PAOX.
Discussion
High levels of DNp73 have been correlated with increased chemoresistance and poor clinical outcome in many cancers. [8] [9] [10] Therefore, understanding mechanisms of how DNp73 expression is regulated in cancers and subsequently, devising strategies to specifically target DNp73 are critical for improving treatment. 31 In this respect, we have previously shown that DNp73 is degraded by c-Jun upon exposure to genotoxic stress via the Az-mediated degradation pathway. 20 However, the exact mechanisms for this process as well as its relevance to DNp73 in mediating chemoresistance was unclear. Az has been shown to degrade several cell-cycle regulatory proteins, including cyclin D1, Smad1 and Aurora A kinase, as well as Mps1, a protein that regulates centrosome (e) Schematic illustrates the proposed mechanism by which genotoxic stresses can induce the degradation of anti-apoptotic DNp73 by activating c-Jun, FosB and JunB. Upon stress, these three AP-1 family members are induced and inhibit the expression of the polyamine catabolic enzyme paox, resulting in the eventual increase in the expression of Az1(p), which leads to the degradation of DNp73, and consequently, chemosensitizes to genotoxic drugs duplication, [32] [33] [34] [35] supporting its role as an inhibitor of tumor cell proliferation and transformation. The expression of Az is tightly controlled at the post-transcriptional level by a þ 1 frameshift translation mechanism, which is regulated by the polyamine biosynthesis pathway. 21 Polyamine homeostasis in cells is modulated by the interplay of several anabolic and catabolic enzymes 22 and we have now shown that paox is specifically targeted by selected AP-1 factors that were activated upon exposure to chemotherapeutic drugs. PAOX is a FAD-dependent oxidase that preferentially retro-converts NASp to spermidine and N-acetylspermidine to putrescine. 22 Putrescine has been shown to be less effective at inducing Az expression compared with spermidine and spermine 36 and therefore inhibition of PAOX would likely lead to higher levels spermine and spermidine relative to putrescine, thus enabling a more pronounced induction of Az in response to genotoxic stress. Many studies have shown that MDL72527, a chemical inhibitor of PAOX, can potentiate apoptosis in several cancer cells both in vitro and in vivo. 37 Conversely, expression of another polyamine catabolic enzyme SSAT under the keratinocyte-specific K6 promoter was shown to promote skin tumors. 38 Interestingly, treatment of these mice with MDL72527 partially counteracted tumor growth, 38 indicating that inhibition of polyamine catabolism can be a potential therapeutic tool to suppress tumor formation. It is noteworthy that enhanced polyamine synthesis has also been shown to promote tumor growth and progression. 38 For example, overexpression of the polyamine biosynthesis enzymes ODC or SAMDC induced malignant transformation. 38, 39 All these observations together suggest that disruption of the homeostatic balance of polyamine ratios and not their overall cellular increase could support tumorigenesis. Our current findings that inhibition of PAOX in DNp73-overexpressing cancer cells increases their sensitivity to apoptosis-inducing chemotherapeutic drugs are consistent with these observations. Interestingly, several studies targeting the polyamine pathways in conjunction with other drugs are currently in clinical trials. 40 However, the direct role of PAOX in tumor formation in vivo and its effects on the levels of the different polyamines warrants further investigation in the future.
PAOX promoter is repressed upon exposure to genotoxic stresses through selective members of the AP-1 transcription family, namely c-Jun, JunB and FosB. c-Jun is known to have a dual role in regulating cell fate where it can either enable apoptotic responses or support growth and proliferation, depending on cellular context. 41 These distinct functions of c-Jun might be determined by the interplay with additional factors such as the interaction with other AP-1 members. Similar to c-Jun, other AP-1 members can also be induced by DNA-damaging signals, 42, 43 indicating their potential involvement in promoting apoptosis with c-Jun. The data presented here show that c-Jun, JunB and FosB are activated by chemotherapeutic drugs to regulate DNp73 degradation. Although JunB is classically known to antagonize some biological functions of c-Jun such as cell proliferation, 27 both also share redundancy on certain target genes, which include Egfr and Proliferin. 44, 45 On the other hand, FosB has been shown to bind in a complex with c-Jun, which was associated with FasL induction and cell death, indicating that c-Jun/FosB dimer has a pro-apoptotic function. 46 Consistently, our data indicate that similar to c-Jun, expression of JunB and FosB could also induce the suppression of paox, increase the level of Az and lead to the subsequent degradation of DNp73. Moreover, JunB and FosB had similar effects in c-Jun-deficient cells, suggesting a level of in-built redundancy to perhaps ensure the efficient regulation of DNp73 levels upon genotoxic insults.
In conclusion, we have unraveled a mechanism through which selective AP-1 transcription factors c-Jun, JunB and FosB induce the degradation of anti-apoptotic DNp73 by Az, via the suppression of polyamine catabolic enzyme PAOX (Figure 5e ). We have therefore identified PAOX as a positive regulator of DNp73 that defines a potential strategy to improve the therapeutic index of cytotoxic drugs in DNp73-overexpressing chemoresistant tumors. Immunoblot analysis and half-life determination. Immunoblot analysis was performed essentially as described. 47 A measure of 50 mg cell lysate was used for analyses and detected using enhanced Chemiluminescent reagent (Amersham Biosciences, Buckinghamshire, UK) or Super signal West Dura (Pierce Biotechnology, Rockford, IL, USA). Antibodies used in this study are: anti-p73 (ER15; Calbiochem, San Diego, CA, USA), anti-p73 (GC15; Calbiochem), anti-HA (Y-11; Santa Cruz Biotechnology), anti-FLAG (M2; Stratagene, La Jolla, CA, USA), anti-c-Jun (Cell Signaling Technology, Danvers, MA, USA), anti-FosB (5G4; Cell Signaling Technology), anti-JunB (P169; Cell Signaling Technology), anti-Fra1 (R20; Santa Cruz Biotechnology), anti-Actin (Sigma), anti-Egfp (Santa Cruz Biotechnology), anti-cyclin D1 (H295; Santa Cruz Biotechnology), anti-Az1(p) (a gift from Dr. John Mitchell, Northern Illinois University), anti-AZI (a gift from Dr. Senya Matsufuji, The Jikei University School of Medicine). For measuring half-life of proteins, cells were treated with 50 mg/ml of CHX and collected at indicated time points for immunoblotting.
Semi-quantitative RT-PCR analyses. Total RNA was prepared from cells using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) and converted into single-strand cDNA using Superscript II Reverse Transcriptase (Invitrogen). Semiquantitative PCR was performed using Taq polymerase (Qiagen) in a 25-ml solution according to manufacturers' protocols. 
Site-directed mutagenesis (SDM) and luciferase reporter assays. The -3045 to -997 paox promoter fragment was cloned into in pGL3 basic or enhancer vector (Promega, Fitchburg, WI, USA). H1299 cells were transiently transfected with 0.2 mg of the relevant plasmids along with the reporter (paox-luc or collagenase-luc) and b-galactosidase constructs to normalize for transfection efficiency. Luciferase assays were performed as described.
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Potential AP-1-binding sites were found using TESS (Transcription Element Search System online software). SDM of the AP-1 sites P1 and P2 were carried out as described. 5 Primers used are: SDM-P1 5 0 -ATGAACAAGCCAAGTTACAGT CAAAGCCAC-3 0 ; SDM-P2 5 0 -ACCGCCCAGAGAATAAGCCCGACTC-3 0 .
ChIP. H1299 cells treated with 5 mM doxorubicin for 0, 3 and 6 h were crosslinked with 1% formaldehyde for 10 min at room temperature. The reaction was stopped by the addition of ice-cold PBS and washed twice with the same buffer. Cells were lysed for 10 min at 4 1C with Triton X-100 lysis buffer (0.25% triton X-100, 10 mM EDTA, 10 mM Tris pH8, 100 mM NaCl and protease inhibitor cocktail (Roche Applied Science, Mannheim, Germany). Samples were centrifuged at 1500 r.p.m. at 4 1C for 5 min and the pellet containing the chromatin fraction was lysed in SDS lysis buffer (1% SDS, 5 mM EDTA, 50 mM Tris pH8 and protease inhibitor cocktail). Chromatin extracts containing genomic DNA were sonicated on ice to an average size of 500 bp and subsequently immunoprecipitated using control anti-IgG, anti c-Jun, anti-FosB or anti-JunB (all from Cell Signalling as previously described) at 4 1C. The immunocomplex was incubated with 50 ml of 50% slurry Protein A-Sepharose beads (Invitrogen) for a further 2 h at 4 1C. Samples were washed with, 1 Â HS buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8, 500mM NaCl), 1 Â LS buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8, 150 mM NaCl), 1 Â 250 mM LiCl buffer at 4 1C for 10 min, followed by 2 Â in TE buffer. DNA/protein complex was eluted three times with 100 ml of extraction buffer (1%SDS and 100 mM NaHCO 3 ) for 15 min. To reverse DNA/protein crosslink, eluted samples were incubated with 200 mM NaCl for 4 h at 65 1C, followed by proteinase K treatment at final concentration of 500 mg/ml at 45 1C for 2 h. DNA was purified for PCR using DNA Qiaquick columns (Qiagen). Semi-quantitative PCR analyses were performed to assess the ChIP-enriched DNA, and non-immunoprecipitated input DNA was included as loading control. The following primers were used: P1 paox promoter forward 5 0 -GGAGAAGTCTTAC AGCATGAT-3 0 , P1 paox promoter reverse 5 0 -ACAAGGTATGTGCTTCTCCTA-3 0 ; P2 paox promoter forward 5 0 -TCCTTAGTCCTGGCATGTCGG-3 0 , P2 paox promoter reverse 5 0 -GTGACCTGGTGTCGCTGGATT-3 0 .
Cell death assay. Cell death was measured by propidium iodide (PI) exclusion assay. SHSY5Y stably transfected with pcDNA or DNp73b cells were treated with indicated doses of doxorubicin or cisplatin with or without MDL72527. Both floating and attached cells were harvested and washed 2 Â with PBS before re-suspension in 2 mg/ml PI. Percentage of Annexin V þ /PI þ cells was measured by flow cytometry (BD Biosciences, FACScalibur, San Jose, CA, USA).
Polyamine measurements. Polyamine levels were measured by HPLC as described previously. 48 Cells treated with doxorubicin or cisplatin, or untreated controls (6 Â 10 5 cells) were harvested and polyamines were extracted from cell lysate with 5% trichloroacetic acid and the supernatant after centrifugation at 27 000 Â g for 15 min at 4 1C was used for polyamine measurement by HPLC. The precipitate was used for measurement of protein content.
Caspase activity assay. Caspase-3 activity was measured by colorimetric assay according to manufacturer's manual (ApoTarget Caspase-3 Kit, Life Sciences, Invitrogen). In brief, cells were lysed in Tris-buffered saline containing reagent and protein concentrations were measured using Comassie Bradford's reagent. 200 mg of the extracted protein were mixed with 2X extraction buffer and 200 mM of DEVD-pNA caspase-3 substrate and incubated for 2 h away from light at 37 1C. Developed reaction was measured at the optical density of 400 nm using spectrophotometry, and the absorbance reading for caspase activity was calculated by subtracting the absorbance of blank samples (without substrate).
